Lixte Biotechnology has enrolled the first patient in a Phase 1b/2 trial of LB-100 and doxorubicin for advanced soft tissue sarcomas. The aim of the study is to find the appropriate dose of LB-100 with a standard dose of doxorubicin, followed by a randomized Phase 2 trial exploring synergy between the two drugs. Lixte hopes that this combination will improve efficacy exhibited by doxorubicin alone during its solo 40-year reign. Keywords: Lixte Biotechnology, Phase 1b/2 trial, LB-100, doxorubicin, advanced soft tissue sarcomas Additional sentence: Soft tissue sarcoma is a rare type of cancer that begins in tissues such as muscle or fat and can be difficult to treat effectively.